| Known as |
Aminoglutethimide |
ClinicalTrials.gov intervention name — accepted as the source's own label NCT00309491 ↗1NCT00006371 ↗
|
| Known as |
Aminoglutetimida |
ChEMBL registry synonym — accepted as the source's own label CHEMBL488 ↗
|
| Known as |
Cytadren |
ChEMBL registry synonym — accepted as the source's own label CHEMBL488 ↗
|
| Known as |
NSC-330915 |
ChEMBL registry synonym — accepted as the source's own label CHEMBL488 ↗
|
| Known as |
Orimeten |
ChEMBL registry synonym — accepted as the source's own label CHEMBL488 ↗
|
| Action |
Inhibit |
“Drugs such as aminoglutethimide or ketoconazole may stop the adrenal glands from producing hormones.” NCT00006371 ↗2“Cytochrome P450 11A1 inhibitor” CHEMBL488 ↗ “Cytochrome P450 19A1 inhibitor” CHEMBL488 ↗
|
| Modality |
Small molecule |
— CHEMBL488 ↗
|
| Route |
Oral |
“Oral aminoglutethimide is administered twice daily for 1 week and then 4 times daily during subsequent weeks.” NCT00006371 ↗
|
| Target |
CYP11A1 |
“Cytochrome P450 11A1 inhibitor” CHEMBL488 ↗
|
| Target |
CYP19A1 |
“Cytochrome P450 19A1 inhibitor” CHEMBL488 ↗
|